前列腺癌立体定向体部放疗及可选局灶病灶消融微推量:专题综述与多中心共识
本文综述了前列腺癌SBRT的前瞻性试验和回顾性分析,重点关注治疗策略与技术,并描述了针对肿瘤病灶同步整合推量的近期文献。此外,讨论了FLAME联盟关于前列腺癌SBRT联合局灶推量至 macroscopic 前列腺内肿瘤结节的多中心共识。
要点
- 前列腺癌SBRT证据来自多项II期试验及近期III期试验。
- 实施SBRT的主要顾虑为晚期泌尿生殖和胃肠道毒性风险。
- FLAME联盟提出对前列腺内宏观肿瘤结节进行局灶推量的共识。
核心结论
- 前列腺癌SBRT在每日临床实践中的实施证据不断增加,但实施方式存在显著差异。
研究设计与样本
- 专题综述,汇总多项前瞻性试验和回顾性分析,并讨论FLAME联盟多中心共识。
主要发现
- 近期发表的试验(包括晚期结局和毒性数据)增加了前列腺癌SBRT用于每日临床实践的证据。
- 前列腺癌SBRT的实施存在显著差异。
- 针对肿瘤病灶的同步整合推量可能在SBRT治疗中创造额外价值。
临床怎么用
- 可参考FLAME联盟多中心共识,对前列腺内宏观肿瘤结节实施SBRT联合局灶推量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stereotactic body radiotherapy (SBRT) for prostate cancer (PCa) is gaining interest by the recent publication of the first phase III trials on prostate SBRT and the promising results of many other phase II trials. Before long term results became available, the major concern for implementing SBRT in PCa in daily clinical practice was the potential risk of late genitourinary (GU) and gastrointestinal (GI) toxicity. A number of recently published trials, including late outcome and toxicity data, contributed to the growing evidence for implementation of SBRT for PCa in daily clinical practice. However, there exists substantial variability in delivering SBRT for PCa. The aim of this topical review is to present a number of prospective trials and retrospective analyses of SBRT in the treatment of PCa. We focus on the treatment strategies and techniques used in these trials. In addition, recent literature on a simultaneous integrated boost to the tumor lesion, which could create an additional value in the SBRT treatment of PCa, was described. Furthermore, we discuss the multicenter consensus of the FLAME consortium on SBRT for PCa with a focal boost to the macroscopic intraprostatic tumor nodule(s).
引用
- Draulans C, De Roover R, van der Heide UA, et al. Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus. Radiother Oncol. 2019. PMID: 31276989. doi:10.1016/j.radonc.2019.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。